| pubmed-article:11529355 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11529355 | lifeskim:mentions | umls-concept:C0019704 | lld:lifeskim |
| pubmed-article:11529355 | lifeskim:mentions | umls-concept:C0043474 | lld:lifeskim |
| pubmed-article:11529355 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11529355 | lifeskim:mentions | umls-concept:C0242648 | lld:lifeskim |
| pubmed-article:11529355 | lifeskim:mentions | umls-concept:C1858460 | lld:lifeskim |
| pubmed-article:11529355 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:11529355 | lifeskim:mentions | umls-concept:C2587213 | lld:lifeskim |
| pubmed-article:11529355 | lifeskim:mentions | umls-concept:C1096776 | lld:lifeskim |
| pubmed-article:11529355 | lifeskim:mentions | umls-concept:C0206012 | lld:lifeskim |
| pubmed-article:11529355 | lifeskim:mentions | umls-concept:C0750729 | lld:lifeskim |
| pubmed-article:11529355 | pubmed:dateCreated | 2001-8-31 | lld:pubmed |
| pubmed-article:11529355 | pubmed:abstractText | A multicenter randomized, double blind, placebo-controlled clinical trial was conducted to evaluate the effectiveness of a short course of oral zidovudine (ZDV) treatment in HIV-1 infected pregnant women, starting at 38 weeks of gestation plus ZDV infusion during labor until delivery, to reduce HIV-1 vertical transmission in non-breast fed infants. One hundred and eighty two asymptomatic antiretroviral naïve HIV-1 infected pregnant women were enrolled. Each patient was randomly allocated into either the ZDV or placebo group. The ZDV group received 250 mg ZDV orally twice a day initiated at 38 weeks' gestation until the onset of labor. During the intrapartum period, ZDV infusion at the rate of 2 mg/kg was administered within the first hour and then continuously infused at the rate of 1 mg/kg/h until delivery. The placebo group received an identical capsule during pregnancy and normal saline infusion during labor until delivery. HIV-1 transmission was documented by nested polymerase chain reaction in infants at birth and at 1, 3 and, 6 months of age. The estimated HIV-1 vertical transmission rate was 14.9 per cent (95% CI = 11.1 to 18.7) and 16.3 per cent (95% CI = 12.3 to 20.9) in ZDV and placebo group, respectively (p > 0.05). The short course ZDV in antiretroviral naïve pregnant women initiated at 38 weeks' gestation plus intrapartum ZDV infusion without treatment in the infants was not effective to prevent HIV-1 vertical transmission. | lld:pubmed |
| pubmed-article:11529355 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11529355 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11529355 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11529355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11529355 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11529355 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11529355 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:11529355 | pubmed:issn | 0125-2208 | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:PhanuphakPP | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:VirutamasenPP | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:Limpongsanura... | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:ThisyakornUU | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:RuxrungthamKK | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:UbolyamSS | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:Thaithumyanon... | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:KongsinPP | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:Chaithongwong... | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:TarounotaiUU | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:Chantheptaewa... | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:Triratwerapon... | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:HanwanichMM | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:HawanonPP | lld:pubmed |
| pubmed-article:11529355 | pubmed:author | pubmed-author:Chulasugondha... | lld:pubmed |
| pubmed-article:11529355 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11529355 | pubmed:volume | 84 Suppl 1 | lld:pubmed |
| pubmed-article:11529355 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11529355 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11529355 | pubmed:pagination | S338-45 | lld:pubmed |
| pubmed-article:11529355 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:meshHeading | pubmed-meshheading:11529355... | lld:pubmed |
| pubmed-article:11529355 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11529355 | pubmed:articleTitle | Short course zidovudine maternal treatment in HIV-1 vertical transmission: randomized controlled multicenter trial. | lld:pubmed |
| pubmed-article:11529355 | pubmed:affiliation | Department of Obstetrics and Gynecology, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. | lld:pubmed |
| pubmed-article:11529355 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11529355 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11529355 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:11529355 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11529355 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:11529355 | pubmed:publicationType | Multicenter Study | lld:pubmed |
